Case Report

Pulmonary Complications of Azanucleoside Therapy in Patients with Myelodysplastic Syndrome and Acute Myelogenous Leukemia

Table 1

Clinical and laboratory characteristics of MDS and AML patients with pulmonary complications treated with azanucleosides therapy.

CaseAge/sexSymptomsCycles of AZAInitiation of symptoms
(days)
Radiographic findingsLung pathologyCRP
(mg/dL)
MDS WHO 2008
classification
CytogeneticR-IPSSANC
(cells/L)
ALC
(cells/L)
Platelet count
(/L)
Ref.

172/MFever, shortness of breath13 Interstitial pneumonitis, ground-glass opacities NA 10.2RAEB-146, XY, der(1;7)(q10;p1) [17/20]Very high9054018000[3]

264/MDry cough, fever, and chills22Left lower lobe infiltrateFibrinous and organizing pneumoniaNAt-MDSNANA14049012000[4]

374/MDry cough, shortness of breath17Nonsegmental consolidation/ground-glass opacitiesNA1.25RAEB-1ComplexVery high630179017000[5]

456/MDry cough, fever 12Nodular opacities, bilateral airspace diseaseInterstitial lung disease, organizing pneumonia with bronchocentric granulomatous patternNARAEB-2NANA750NA12000[6]

571/MFever, shortness of breath114 Diffuse bilateral interstitial/alveolar infiltratesFocal areas of intra-alveolar acute inflammation and necrosisNANANANANANANA[7]

674/FFever, dry cough, and shortness of breath25Reticulonodular and ground-glass shadowing and small pleural effusionsNANANAComplexVery high4300NA342000[8]

7CaseShortness of breath11330 Bilateral interstitial lung infiltratesNA 0.68MDS derived AML ComplexVery high17501250579000Case

CRP: C-reactive protein; ANC: absolute neutrophil count; ALC: absolute lymphocyte count; NA: not available; t-MDS: treatment-related MDS; RAEB: refractory anemia excess blast; karyotype included 10 chromosomal abnormalities.